These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
191 related items for PubMed ID: 2840815
1. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. Uretsky BF, Shaver JA, Liang CS, Amin D, Shah PK, Levine TB, Walinsky P, LeJemtel T, Linnemeier T, Rush JE. Am Heart J; 1988 Aug; 116(2 Pt 1):480-8. PubMed ID: 2840815 [Abstract] [Full Text] [Related]
4. Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. Stone CK, Uretsky BF, Linnemeier TJ, Shah PK, Amin DK, Snapinn SM, Rush JE, Langendörfer A, Liang CS. Am J Cardiol; 1989 Mar 01; 63(9):567-70. PubMed ID: 2537566 [Abstract] [Full Text] [Related]
5. Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. Dickstein K. J Cardiovasc Pharmacol; 1987 Mar 01; 9 Suppl 3():S73-81. PubMed ID: 2442558 [Abstract] [Full Text] [Related]
12. Clinical experience with lisinopril in congestive heart failure. Focus on the older patient. Giles TD. Drugs; 1990 Mar 01; 39 Suppl 2():17-22. PubMed ID: 2160883 [Abstract] [Full Text] [Related]
13. Lisinopril versus placebo in older congestive heart failure patients. Lewis GR. Am J Med; 1988 Sep 23; 85(3B):48-54. PubMed ID: 2844088 [Abstract] [Full Text] [Related]
14. The acute hemodynamic, hormonal, and pharmacokinetic properties of oral spirapril in patients with moderate to severe heart failure. van den Broek SA, van Bruggen A, de Graeff PA, Hillege H, van Gilst WH, Wesseling H, Lie KI. J Cardiovasc Pharmacol; 1991 Oct 23; 18(4):614-21. PubMed ID: 1724540 [Abstract] [Full Text] [Related]
17. A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure. Insel J, Mirvis DM, Boland MJ, Cinquegrani MP, Shanes J, Rubin SA, Whalen JJ. Clin Pharmacol Ther; 1989 Mar 23; 45(3):312-20. PubMed ID: 2537699 [Abstract] [Full Text] [Related]
18. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE. Arterioscler Thromb Vasc Biol; 2004 Jun 23; 24(6):1043-8. PubMed ID: 15105283 [Abstract] [Full Text] [Related]
19. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations. DiCarlo L, Chatterjee K, Parmley WW, Swedberg K, Atherton B, Curran D, Cucci M. J Am Coll Cardiol; 1983 Nov 23; 2(5):865-71. PubMed ID: 6313787 [Abstract] [Full Text] [Related]
20. Angiotensin converting enzyme inhibitors. Disparities in the mechanism of their antihypertensive effect. Garavaglia GE, Messerli FH, Nunez BD, Schmieder RE, Frohlich ED. Am J Hypertens; 1988 Jul 23; 1(3 Pt 3):214S-216S. PubMed ID: 2843195 [Abstract] [Full Text] [Related] Page: [Next] [New Search]